




PURPLE TRANSLATIONAL REGISTRY

PANCREATIC CANCER: UNDERSTANDING ROUTINE PRACTICE & LIFTING END RESULTS

In this edition:

- Welcome to new sites
- New PURPLE Website – 2023
- Current studies
- Recent publications
- Registry data snapshot
- New PURPLE team member



Welcome to the new sites who have recently joined PURPLE:

- Port Macquarie, NSW
- Toowoomba Base Hospital, QLD
- Ng Teng Fong General Hospital, Singapore
- Canberra Hospital, ACT
- Christchurch & Waitematā, New Zealand

If your hospital or cancer centre is interested in joining the PURPLE Registry and contributing data as a participating site please [contact us](#).

Coming soon – New Website !


In the coming months we will be launching our new website – [The PURPLE Translational Platform](#)

The website will bring together information for clinicians, researchers and patients by:

- Creating a single comprehensive platform that supports data sharing and research collaboration across treatment centres and research labs.
- Providing an up-to-date listing of current pancreatic cancer trials available in Australia.

The website will facilitate translational research opportunities by assisting clinicians and researchers to leverage PURPLE Registry data for studies.

Current studies leveraging PURPLE Translational Registry data



DYNAMIC-Pancreas – using ctDNA to inform adjuvant therapy in resected pancreatic cancer.

DIRECT/insPIRE – chemotherapy + NanoKnife in unresectable stage III pancreatic cancer.

Australian Pancreatic Cancer Familial Screening Program - led by Alina Stoita, SVHS.

For more information on recruiting studies, contact: Roslynn.Murphy@mh.org.au

Recent Publications

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicenter PURPLE pancreatic cancer registry.

Lead Author: Jordan Santucci

Published in: European Journal of Cancer, <https://doi.org/10.1016/j.ejca.2022.06.042>

Key Findings: This retrospective analysis of prospectively collected PURPLE clinical registry data reports outcomes in advanced pancreatic ductal adenocarcinoma (PDAC) patients treated with palliative chemotherapy.

The primary aim was to compare survival outcomes between first-line treatment regimens and subsequent therapy in a real-world population to determine if an optimal therapeutic sequence is associated with survival benefit.

In this study, 615 patients received palliative-intent chemotherapy. Median overall survival (mOS) was comparable between patients receiving first-line (1L) Gemcitabine/Nab-Paclitaxel (n=376) and those receiving FOLFIRINOX (n=73), with 38% proceeding to second line chemotherapy (2L). 2L was associated with longer mOS compared to 1L treatment alone.

With 2L treatment following prior FOLFIRINOX or Gemcitabine/Nab-Paclitaxel, mOS did not differ significantly, whilst median progression-free survival was longer with prior FOLFIRINOX.

Conclusion: There was no significant difference in overall survival between either 1L chemotherapy choice, despite the patients receiving FOLFIRINOX being younger, fitter and more likely to have localised disease. However, FOLFIRINOX was associated with delayed progression. In the absence of phase III RCT data, clinicians should be comfortable using either Gemcitabine/Nab-Paclitaxel or FOLFIRINOX as 1L chemotherapy in advanced PDAC.





Fig. 1. Kaplan–Meier estimates of OS for 109 locally-advanced PDAC patients receiving first-line palliative Gem/Nab-P (median OS 13.2 [95% CI 11.3–15.1] months) versus 23 patients receiving FOLFIRINOX (median OS 11.4 [95% CI 4.8–17.9] months), Log rank P = 0.96

PURPLE Registry Snapshot



There are now over 3150 pancreatic cancer patients recorded in the PURPLE registry database.

New PURPLE Registry team member



In late 2022, the PURPLE team welcomed onboard a new PURPLE Registry Project Manager. [Nadia Ayres](#) will be the administering the Registry database and website going forward as well as being the contact for research study proposals and patient enquiries. [Michael Harold](#) will still be available to provide backup registry support as required. Nadia and the team are looking forward to launching the new website in 2023 and keeping you updated with quarterly newsletter publications.



The PURPLE team extend our thanks to all existing and on-boarding sites for being part of the ever-expanding PURPLE Translational Platform and its repertoire of clinical trials and research studies. We eagerly await the results of upcoming presentations and publications that leverage the data from PURPLE's real-world population and remain committed to improving outcomes for patients.

